Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 13/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 11/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185185 | 1.00 | PIM1 (0.50) | PIM1PIM2PIM3PBKKCNH2 | |
| SCHEMBL2186093 | 0.92 | PIM1 (0.48) | PIM1PIM2PIM3PBKKCNH2 | |
| SCHEMBL2186117 | 0.92 | PIM1 (0.48) | PIM1PIM2PIM3PBKKCNH2 | |
| SCHEMBL2184958 | 0.86 | PIM1 (0.49) | PIM1PIM2PIM3KCNH2CYP2C19 | |
| SCHEMBL2185217 | 0.86 | PIM2 (0.49) | PIM1PIM2PIM3KCNH2CYP2C19 | |
| SCHEMBL2184264 | 0.86 | PIM2 (0.49) | PIM1PIM2PIM3KCNH2CYP2C19 | |
| SCHEMBL2184956 | 0.86 | PIM1 (0.49) | PIM1PIM2PIM3KCNH2CYP2C19 | |
| SCHEMBL2184907 | 0.84 | PIM2 (0.53) | PIM1PIM2PIM3KCNH2 | |
| SCHEMBL12391074 | 0.84 | PIM2 (0.53) | PIM1PIM2PIM3KCNH2 | |
| SCHEMBL2184908 | 0.84 | PIM2 (0.53) | PIM1PIM2PIM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | claimed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | claimed |
| EP-2342190-A1 | BICYCLIC KINASE INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | claimed |
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2342190-A1 | BICYCLIC KINASE INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.